Supplementing any of the Abl1 inhibitors currently in use in CML by axitinib was not shown to achieve the ultimate goal of preventing T315I from emerging, but could slightly lower the odds for this. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.